CFTR: New insights into structure and function and implications for modulation by small molecules

Bertrand Kleizen; John Hunt; Isabelle Callebaut; Tzyh-Chang Hwang; Isabelle Sermet-Gaudelus; Sylvia Hafkemeyer; David N Sheppard

doi:10.1016/j.jcf.2019.10.021

CFTR: New insights into structure and function and implications for modulation by small molecules

Bertrand Kleizen^*, John Hunt, Isabelle Callebaut, Tzyh-Chang Hwang, Isabelle Sermet-Gaudelus, Sylvia Hafkemeyer, David N Sheppard

^*Corresponding author for this work

Research output: Contribution to journal › Article (Academic Journal) › peer-review

16 Citations (Scopus)

91 Downloads (Pure)

Abstract

Structural biology and functional studies are a powerful combination to elucidate fundamental knowledge about the cystic fibrosis transmembrane conductance regulator (CFTR). Here, we discuss the latest findings, including how clinically-approved drugs restore function to mutant CFTR, leading to better clinical outcomes for people with cystic fibrosis (CF). Despite the prospect of regulatory approval of a CFTR-targeting therapy for most CF mutations, strenuous efforts are still needed to fully comprehend CFTR structure-and-function for the development of better drugs to enable people with CF to live full and active lives.

Original language	English
Pages (from-to)	S19-S24
Number of pages	6
Journal	Journal of Cystic Fibrosis
Volume	19
Issue number	Supplement 1
Early online date	21 Nov 2019
DOIs	https://doi.org/10.1016/j.jcf.2019.10.021
Publication status	Published - Mar 2020

Keywords

membrane protein
ABC-transporter
mutations
F508del
therapy
clinical drugs
cystic fibrosis

Access to Document

10.1016/j.jcf.2019.10.021

Full-text PDF (accepted author manuscript)
This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at https://www.sciencedirect.com/science/article/abs/pii/S1569199319309361. Please refer to any applicable terms of use of the publisher.
Accepted author manuscript, 372 KBLicence: CC BY-NC-ND

Handle.net

Persistent link

Cite this

@article{28d184f5f7d24cb8adaf150fabe8d048,

title = "CFTR: New insights into structure and function and implications for modulation by small molecules",

abstract = "Structural biology and functional studies are a powerful combination to elucidate fundamental knowledge about the cystic fibrosis transmembrane conductance regulator (CFTR). Here, we discuss the latest findings, including how clinically-approved drugs restore function to mutant CFTR, leading to better clinical outcomes for people with cystic fibrosis (CF). Despite the prospect of regulatory approval of a CFTR-targeting therapy for most CF mutations, strenuous efforts are still needed to fully comprehend CFTR structure-and-function for the development of better drugs to enable people with CF to live full and active lives. ",

keywords = "membrane protein, ABC-transporter, mutations, F508del, therapy, clinical drugs, cystic fibrosis",

author = "Bertrand Kleizen and John Hunt and Isabelle Callebaut and Tzyh-Chang Hwang and Isabelle Sermet-Gaudelus and Sylvia Hafkemeyer and Sheppard, \{David N\}",

year = "2020",

month = mar,

doi = "10.1016/j.jcf.2019.10.021",

language = "English",

volume = "19",

pages = "S19--S24",

journal = "Journal of Cystic Fibrosis",

issn = "1569-1993",

publisher = "Elsevier B.V.",

number = "Supplement 1",

}

TY - JOUR

T1 - CFTR

T2 - New insights into structure and function and implications for modulation by small molecules

AU - Kleizen, Bertrand

AU - Hunt, John

AU - Callebaut, Isabelle

AU - Hwang, Tzyh-Chang

AU - Sermet-Gaudelus, Isabelle

AU - Hafkemeyer, Sylvia

AU - Sheppard, David N

PY - 2020/3

Y1 - 2020/3

N2 - Structural biology and functional studies are a powerful combination to elucidate fundamental knowledge about the cystic fibrosis transmembrane conductance regulator (CFTR). Here, we discuss the latest findings, including how clinically-approved drugs restore function to mutant CFTR, leading to better clinical outcomes for people with cystic fibrosis (CF). Despite the prospect of regulatory approval of a CFTR-targeting therapy for most CF mutations, strenuous efforts are still needed to fully comprehend CFTR structure-and-function for the development of better drugs to enable people with CF to live full and active lives.

AB - Structural biology and functional studies are a powerful combination to elucidate fundamental knowledge about the cystic fibrosis transmembrane conductance regulator (CFTR). Here, we discuss the latest findings, including how clinically-approved drugs restore function to mutant CFTR, leading to better clinical outcomes for people with cystic fibrosis (CF). Despite the prospect of regulatory approval of a CFTR-targeting therapy for most CF mutations, strenuous efforts are still needed to fully comprehend CFTR structure-and-function for the development of better drugs to enable people with CF to live full and active lives.

KW - membrane protein

KW - ABC-transporter

KW - mutations

KW - F508del

KW - therapy

KW - clinical drugs

KW - cystic fibrosis

UR - http://www.scopus.com/inward/record.url?scp=85075808041&partnerID=8YFLogxK

U2 - 10.1016/j.jcf.2019.10.021

DO - 10.1016/j.jcf.2019.10.021

M3 - Article (Academic Journal)

C2 - 31759907

SN - 1569-1993

VL - 19

SP - S19-S24

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

IS - Supplement 1

ER -

CFTR: New insights into structure and function and implications for modulation by small molecules

Abstract

Keywords

Access to Document

Handle.net

Other files and links

Fingerprint

Anion Carriers for Channel Replacement Therapy

Cite this

CFTR: New insights into structure and function and implications for modulation by small molecules

Abstract

Keywords

Access to Document

Handle.net

Other files and links

Fingerprint

Projects

Anion Carriers for Channel Replacement Therapy

Cite this